针对抗瘤CAR-T细胞免疫疗法的点的表达特征
Peng Zhang1,2, Chunzhao Li1,2, Yi Wang1,2
1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Nan Si Huan Xi Lu 119, Beijing, 100070, China.
Journal of neuro-oncology
|October 29, 2024
概括
像B7H3和CSPG4这样的CAR-T点在质瘤中表现出不同的表达. 目标组合改善了覆盖范围,与恶性和免疫表型相关,以获得更好的质瘤治疗策略.
科学领域:
- 神经瘤学神经瘤学
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法在质瘤治疗方面表现有前途.
- 了解常见的抗质瘤CAR-T标的表达模式对于优化治疗策略至关重要.
- 质瘤异质性对向治疗提出了挑战.
研究的目的:
- 分析不同等级和分子亚型的质瘤中B7H3,CSPG4,EGFRvIII,HER2和IL-13Ra2的表达.
- 调查CAR-T标表达和质瘤恶性/免疫表型之间的相关性,包括免疫逃避,干性,抗原呈现和血管生成.
主要方法:
- 在质瘤组织上使用OpalTM多重体免疫光染色.
- 检测了CAR-T目标和相关的表型生物标志物.
主要成果:
- 在质瘤亚型中观察到CAR-T标表达的显著异质性,质母细胞瘤多形 (GBM) 显示了最高的整体表达.
- 最常见的目标是CSPG4 (84%的病例),其次是B7H3 (64%). 在GBM中B7H3的表达很高 (94%),而CSPG4在寡质瘤 (94%) 和星系细胞瘤 (80%) 中占主导地位.
- 联合准策略增强了瘤覆盖范围. PD-L1,CD133和CD31的表达与特定的目标阳性细胞相关,表明与免疫逃避和血管生成的联系.
结论:
- 抗质瘤CAR-T标在质瘤亚型中表现出异质的表达和明显的瘤覆盖模式.
- 目标表达与质瘤恶性和免疫表型密切相关,为精细的治疗方法提供了潜力.
相关概念视频
01:27Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K